Navigation Links
Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
Date:6/22/2013

of nocturnal hypoglycemia (0.9 vs. 1.2 events/30 days). Hypoglycemia rates in LY2605541-treated patients were statistically higher during some daytime and evenings, which resulted in the need to reduce mealtime insulin doses during the study.[1]

"This additional analysis showed that patients treated with LY2605541 achieved effective glycemic control with less mealtime insulin, which is exciting because it further supports our hypothesis that LY2605541 has a novel mechanism of action," said David Kendall, M.D., distinguished medical fellow, Lilly Diabetes. "We are encouraged by the potential benefits LY2605541 may offer patients and are pleased that our data support its ongoing development."

LY2605541, which was discovered and developed in Lilly Research Laboratories, is currently in Phase III clinical trials, and is among several diabetes molecules in Lilly's late-stage pipeline. The company has approximately a dozen potential new medicines for the treatment of diabetes and its related conditions, encompassing both large and small molecules, and targeting a variety of mechanisms.

About the Phase II Study Analysis
The Phase II, randomized, open-label, 2x2 crossover study evaluated whether LY2605541 was non-inferior (similar) to insulin glargine in reducing daily mean blood glucose in adults with type 1 diabetes. One hundred thirty-seven patients received LY2605541 or insulin glargine once daily, plus mealtime insulin, for eight weeks; they then switched treatments for an additional eight weeks. Daily mean blood glucose values were obtained from self-monitoring of blood glucose (SMBG) profiles (blood glucose readings before and two hours after a meal, at bedtime and at 3 a.m.) collected on three separate days the week prior to each visit. Hypoglycemic events (i.e., blood glucose less than 70 mg/dL) were captured throughout the study. All insulins were adjusted to optimize glycemic control.

The add
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
5. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FRANCISCO , Aug. 21, 2014 /PRNewswire/ ... Food and Drug Administration (FDA) has granted ... detect atrial fibrillation (AFib), the most common ... process (algorithm) instantly detects if patients are ... taken on the mobile phone based AliveCor® ...
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... Aug. 21, 2014  The board of directors of ... provider of clinical trial imaging solutions, today announced that ... financial officer, effective immediately.  Mr. Groff has held the ... He joined VirtualScopics in January 2006 as an accounting ... "When the board of VirtualScopics asked Jim ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
(Date:8/21/2014)... Australian scientists say a commercially available ... been used to successfully fight mesothelioma in lab mice. ... new research. Click here to read it now. ... treated mesothelioma cells with the S. aureus ... while simultaneously stimulating a stronger anti-tumor response in healthy ...
(Date:8/21/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national Chief ... Center (SGMC) in Valdosta, GA. The top ... E. Smith has recently placed more than 900 healthcare ... for profit healthcare organization headquartered in Valdosta, GA., and ...
(Date:8/21/2014)... Denver marketing agency Webolutions® ... American Lung Association in Colorado’s 2014 Run the ... as a sponsor,” said Curt Huber, Chief Development Officer, ... American Lung Association in Colorado, “and we’re eager to ... role they’ve defined.” , Webolutions has also created and ...
(Date:8/21/2014)... August 21, 2014 If chocolate is good ... will soon be very happy and healthy. Tracie is the ... Break ” contest. She and three of her coworkers will ... luxuriate at the world-famous Chocolate Spa® at The Hotel Hershey® ... third year working in the ambulatory surgery center at Connecticut ...
(Date:8/21/2014)... Centre, NY (PRWEB) August 21, 2014 ... law firm with over 25 years of experience advocating ... prescription drugs and defective medical devices, announces the launch ... information to those women who believe they have been ... site offers valuable information about the severe adverse side ...
Breaking Medicine News(10 mins):Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:South Georgia Medical Center Retains B. E. Smith to Recruit New Chief Nurse Executive 2Health News:South Georgia Medical Center Retains B. E. Smith to Recruit New Chief Nurse Executive 3Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:Connecticut Nurse Wins a Sweet Prize from California Casualty 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2
... just come several steps closer to understanding change blindness ... changes to scenes around them with new research that ... people are more likely to notice. These findings ... Vision article, "A semi-automated approach to balancing bottom-up salience ...
... unsanitary water, expense, experts note , WEDNESDAY, June 16 ... are faced with an awful choice: breast-feed their babies and ... of reach because of cost or can sicken the baby ... Now, two new studies find that giving pregnant and nursing ...
... ... Medical Research, in collaboration with colleagues at the Karolinska Institute, have identified the protein ... the development of new drugs that selectively block this pathway and prevent sickness syndromes. ... Manhasset, NY ...
... how an online learning community works for a group ... continued web interaction. , Urban Carln, Department of ... of general practitioners interact via an e-mail list. The ... community for exchange of knowledge and experience. The submitted ...
... mutism and lower cranial nerve paralysis (locked-in syndrome), ... through vertical gaze and upper eyelid movements, using ... issue of Mayo Clinic Proceedings , researchers ... who also had dancing eye syndrome (opsoclonus-myoclonus syndrome). ...
... of Physicians (ACP) today said it supports the announcements of ... by President Obama and the U.S. Department of Health and ... specific reference to workforce training as "part of a larger ... and patients and to improve the quality of care." ...
Cached Medicine News:Health News:Researchers predict human visual attention using computer intelligence for the first time 2Health News:Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows 2Health News:Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows 3Health News:Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows 4Health News:Unlocking the Immune System's Response to Infection and Injury 2Health News:Unlocking the Immune System's Response to Infection and Injury 3Health News:Clear rules facilitate continued Web interaction among general practitioners 2Health News:Mayo Clinic Proceedings: Gabapentin opens window of communication 2Health News:ACP supports announcement of investments in expansion of primary care workforce 2
... the parafollicular C-cells of the thyroid gland ... major action of calcitonin is to lower ... resulting in decreased mobilization of calcium from ... in conditions associated with high levels of ...
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
Erbium Laser with Sapphire Erbium Handpiece for Dermatological and Cosmetic Surgery...
... The Bio-Optics LSM-12000 is a new High ... new tool in anterior segment diagnostics and ... to operate, easy to maintain, and very ... the only High Magnification Slit-Lamp Biomicroscope available ...
Medicine Products: